Shohei Eto
A5039229894- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- Diabetes and associated disorders
- Connective tissue disorders research
- Congenital Diaphragmatic Hernia Studies
- Acute Myeloid Leukemia Research
- Inflammasome and immune disorders
- Neurogenetic and Muscular Disorders Research
- DNA Repair Mechanisms
- Acute Lymphoblastic Leukemia research
Hiroshima University
2017-2022
Hiroshima Prefectural Hospital
2018
Circulating autoantibodies (auto-Abs) neutralizing high concentrations (10 ng/mL, in plasma diluted 1 to 10) of IFN-α and/or -ω are found about 10% patients with critical COVID-19 pneumonia, but not subjects asymptomatic infections. We detect auto-Abs 100-fold lower, more physiological, (100 pg/mL, 1/10 dilutions plasma) 13.6% 3,595 COVID-19, including 21% 374 > 80 years, and 6.5% 522 severe COVID-19. These antibodies also detected 18% the 1,124 deceased (aged 20 days-99 years; mean: 70...
Significance There is growing evidence that preexisting autoantibodies neutralizing type I interferons (IFNs) are strong determinants of life-threatening COVID-19 pneumonia. It important to estimate their quantitative impact on mortality upon SARS-CoV-2 infection, by age and sex, as both the prevalence these risk death increase with higher in men. Using an unvaccinated sample 1,261 deceased patients 34,159 individuals from general population, we found against IFNs strongly increased...
Abstract SARS-CoV-2 infection fatality rate (IFR) doubles with every five years of age from childhood onward. Circulating autoantibodies neutralizing IFN-α, IFN-ω, and/or IFN-β are found in ~20% deceased patients across groups. In the general population, they ~1% individuals aged 20-70 and >4% those >70 old. With a sample 1,261 34,159 uninfected individuals, we estimated both IFR relative risk death (RRD) groups for carrying type I IFNs, to non-carriers. For IFN-α2 or RRD was 17.0[95%...
Autoantibodies (aAbs) to type I interferons (IFNs) have been found in <1% of individuals under the age 60 general population, with prevalence increasing among those over 65. Neutralizing autoantibodies (naAbs) IFNs at least 15% patients life-threatening COVID-19 pneumonia several cohorts primarily European descent. We aimed define aAbs IFN-α2 3,456 Japanese controls aged 20-91 and naAbs IFN-ω 627 0-104, whom were 170 critical, 235 severe, 112 moderate, 105 mild, 5 asymptomatic infections.
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by authors. Any queries (other than missing content) should be directed to corresponding author article.